About the Company
uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $QURE News
uniQure NV (QURE) Reports 2023 Financial Results Amid Strategic Reorganization
Cash Position: uniQure NV (NASDAQ:QURE) reported a robust cash reserve of approximately $618 million as of December 31, 2023, expected to fund operations into Q2 2027. Revenue: Revenue for 2023 ...
uniQure NV QURE
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Have Been Cutting Their Estimates
It's been a sad week for uniQure N.V. (NASDAQ:QURE), who've watched their investment drop 12% to US$5.59 in the week since the company reported its annual result. The results were mixed overall ...
Uniqure NV earnings missed by $0.05, revenue fell short of estimates
Investing.com - Uniqure NV (NASDAQ: QURE) reported fourth quarter EPS of $-1.50, $0.05 worse than the analyst estimate of $-1.45. Revenue for the quarter came in at $2.31M versus the consensus ...
QURE uniQure N.V.
The chart has 1 X axis displaying Time. Data ranges from 2021-12-30 21:00:00 to 2033-12-30 21:00:00. The chart has 1 Y axis displaying values. Data ranges from -6.460890767 to 7.040788732.
Maintaining Hold on uniQure: Balancing Long-Term Potential Against Near-Term Uncertainties
Begin your TipRanks Premium journey today. uniQure (QURE) Company Description: uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to ...
uniQure NV CEO Matthew Kapusta Sells 27,904 Shares
uniQure NV (NASDAQ:QURE), a company specializing in gene therapy, has reported a significant insider transaction. CEO and Managing Director Matthew Kapusta sold 27,904 shares of the company on ...
Maintaining Hold on uniQure Amid Regulatory Uncertainty and Financial Considerations
Begin your TipRanks Premium journey today. uniQure (QURE) Company Description: uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to ...
uniQure N.V. (0EE0.L)
~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history ...
Uniqure NV earnings missed by $0.05, revenue fell short of estimates
Investing.com - Uniqure NV (NASDAQ: QURE) reported fourth quarter EPS of $-1.50, $0.05 worse than the analyst estimate of $-1.45. Revenue for the quarter came in at $2.31M versus the consensus ...
uniQure NV (QURE) Reports 2023 Financial Results Amid Strategic Reorganization
Cash Position: uniQure NV (NASDAQ:QURE) reported a robust cash reserve of approximately $618 million as of December 31, 2023, expected to fund operations into Q2 2027. Revenue: Revenue for 2023 ...
Loading the latest forecasts...